Merck & Co.KPI data tables
Merck & Co. operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Livestock | Companion Animal |
|---|---|---|
| Q3 2026 | 1,048 | 628 |
| Q2 2026 | 1,041 | 734 |
| Q1 2026 | 1,064 | 727 |
| Q4 2025 | 987 | 518 |
| Q3 2025 | 1,023 | 592 |
| Q2 2025 | 961 | 685 |
| Q1 2025 | 924 | 664 |
| Q4 2024 | 889 | 508 |
| Q3 2024 | 886 | 601 |
| Q2 2024 | 837 | 645 |
| Q1 2024 | 850 | 661 |
Source: Merck & Co. Form 8-K Exhibit 99.1 Franchise / Key Product Sales table, Livestock and Companion Animal rows, amounts in millions. Q2 2026 https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm Livestock 1,064 / 1,041 and Companion Animal 727 / 734 in Q1 and Q2 2026 (Animal Health 1,791 / 1,775). Q3 2026 https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm Livestock 1,048 and Companion Animal 628 (Animal Health 1,676), September YTD Livestock 3,154 and Companion Animal 2,089. FY 2025 https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm Livestock Q1-Q4 2025 924 / 961 / 1,023 / 987, full year 3,896, and 2024 850 / 837 / 886 / 889, full year 3,462; Companion Animal Q1-Q4 2025 664 / 685 / 592 / 518, full year 2,458, and 2024 661 / 645 / 601 / 508, full year 2,415. BRAVECTO Q2 2026 $359 million versus $335 million in Q2 2025, Q3 2026 $264 million versus $262 million in Q3 2025, and FY 2025 $1.1 billion, from the same Q2 2026, Q3 2026 and FY 2025 exhibits (prose, not a table row).
| Period | Gardasil/Gardasil 9 sales |
|---|---|
| Q3 2026 | 1,995 |
| Q2 2026 | 1,169 |
| Q1 2026 | 1,069 |
| Q4 2025 | 1,031 |
| Q3 2025 | 1,749 |
| Q2 2025 | 1,126 |
| Q1 2025 | 1,327 |
| Q4 2024 | 1,550 |
| Q3 2024 | 2,306 |
| Q2 2024 | 2,478 |
| Q1 2024 | 2,249 |
Source: Merck & Co. Form 8-K Exhibit 99.1 Franchise / Key Product Sales table, Gardasil/Gardasil 9 row, amounts in millions. Q2 2026 https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm Q1 2026 1,069, Q2 2026 1,169, June YTD 2,238. Q3 2026 https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm Q3 2026 1,995, September YTD 4,232. FY 2025 https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm Q1-Q4 2025 1,327 / 1,126 / 1,749 / 1,031, full year 5,233; Q1-Q4 2024 2,249 / 2,478 / 2,306 / 1,550, full year 8,583. Form 10-K year ended 31 Dec 2025 https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm 39% decline, China shipment pause from February 2025. 2024 four quarters sum to 8,583. 2025 four quarters sum to 5,233. Q1 plus Q2 2026 equals printed June YTD 2,238. Q1 plus Q2 plus Q3 2026 is 4,233 versus printed September YTD 4,232 (1 million rounding).
| Period | Keytruda sales |
|---|---|
| Q3 2026 | 7,771 |
| Q2 2026 | 7,904 |
| Q1 2026 | 7,906 |
| Q4 2025 | 8,337 |
| Q3 2025 | 8,142 |
| Q2 2025 | 7,956 |
| Q1 2025 | 7,205 |
| Q4 2024 | 7,836 |
| Q3 2024 | 7,429 |
| Q2 2024 | 7,270 |
| Q1 2024 | 6,947 |
Source: Merck & Co. Form 8-K Exhibit 99.1 Franchise / Key Product Sales table, Keytruda row, amounts in millions. Q2 2026 (filed 4 Aug 2026) https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm Q1 2026 7,906, Q2 2026 7,904, June YTD 15,810. Q3 2026 (filed 29 Oct 2026) https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm Q3 2026 7,771, September YTD 23,581 (QLEX 830 is a separate row). FY 2025 (filed 3 Feb 2026) https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm Q1-Q4 2025 7,205 / 7,956 / 8,142 / 8,337, full year 31,641; Q1-Q4 2024 6,947 / 7,270 / 7,429 / 7,836, full year 29,482. Q1 2026 exhibit https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm reprints Q1 2026 at 7,906. Form 10-K year ended 31 Dec 2025 https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm Keytruda 49% of 2025 sales. 2024 four quarters sum to 29,482. 2025 four quarters sum to 31,640 versus printed 31,641 (1 million rounding).
| Period | WINREVAIR sales |
|---|---|
| Q3 2026 | 694 |
| Q2 2026 | 588 |
| Q1 2026 | 525 |
| Q4 2025 | 467 |
| Q3 2025 | 360 |
| Q2 2025 | 336 |
| Q1 2025 | 280 |
| Q4 2024 | 200 |
| Q3 2024 | 149 |
| Q2 2024 | 70 |
Source: Merck & Co. Form 8-K Exhibit 99.1 Franchise / Key Product Sales table, Winrevair row, amounts in millions. Q2 2026 https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm Q1 2026 525, Q2 2026 588, June YTD 1,114. Q3 2026 https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm Q3 2026 694, September YTD 1,808. FY 2025 https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm Q1-Q4 2025 280 / 336 / 360 / 467, full year 1,443; Q2-Q4 2024 70 / 149 / 200, full year 419 (Q1 2024 blank). US patient and prescription marks: Q4 2025 presentation https://www.merck.com/wp-content/uploads/sites/124/2026/02/4Q25-Merck-Earnings-Presentation.pdf more than 1,500 new patients and more than 27,000 prescriptions; Q1 2026 presentation https://www.merck.com/wp-content/uploads/sites/124/2026/04/1Q26-Merck-Earnings-Presentation.pdf more than 1,600 and more than 29,500; Q2 2026 presentation https://www.merck.com/wp-content/uploads/sites/124/2026/08/2Q26-Merck-Earnings-Presentation.pdf about 1,800 and more than 34,000.